Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Dr. Gabriel Hortobagyi, Pioneer of Tumor-Shrinking Treatment Before Breast Cancer Surgery, Receives Award

Dr. Gabriel Hortobagyi, Pioneer of Tumor-Shrinking Treatment Before Breast Cancer Surgery, Receives Award

Dr. Gabriel N. Hortobagyi received the ASCO 2018 Gianni Bonadonna Breast Cancer Award. First established in 2007 in honor of cancer research pioneer Gianni Bonadonna, this award recognizes active clinical and/or translational (from basic science to clinical practice) researchers in breast cancer with exceptional mentoring abilities. Italian physician Gianni Bonadonna discovered adjuvant (protective postoperative) treatment.

Over the past 40 years, Dr. Gabriel N. Hortobagyi has been a leader in clinical and translational breast cancer research. He is a professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. He is known for his outstanding work in breast cancer treatment, particularly the use of preoperative chemotherapy.

Treatments used to shrink a tumor before surgery are called neoadjuvant therapy. In cancer medicine, neoadjuvant therapy is most commonly preferred for breast cancer that has metastasized to the axillary lymph nodes. It is also a preferred way to begin treatment to shrink tumors too large to operate on at diagnosis and in patients with stage 2 and stage 3, HER2-positive or triple-negative breast cancer .

Comparison of neoadjuvant and adjuvant treatment in breast cancer

Dr. Hortobagyi also has advanced expertise in clinical trial design, implementation and analysis. He developed important clinical trial concepts and defined the patient groups needed to test them.

In recent years, Dr. Hortobagyi focused his research on the clinical development of the newest drugs for hormone positive breast cancer, namely CDK4 / 6 inhibitors . MONALEESA-2 was a clinical trial he designed, helped conduct and led. It evaluated treatment efficacy and safety in patients with hormone receptor-positive metastatic breast cancer, using letrozole in combination with ribociclib (marketed as Kisquali). He also worked with palbociclib (Ibrance) and initiated two phase III trials evaluating the efficacy of ribociclib in adjuvant (protective postoperative) treatment.

Dr. Hortobagyi is a former member of the ASCO Board of Directors and served as ASCO President during 2006 - 2007.

Sources

ASCO Honors Leaders in Cancer Care With 2018 Special Awards.
connection.asco.org

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Dr. Gabriel Hortobagyi, Pioneer of Tumor-Shrinking Treatment Before Breast Cancer Surgery, Receives Award

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy